August 14, 2026

Consolidated Financial Results for the Fiscal Year Ended June 30, 2026 (Under Japanese GAAP)

Company name: Asahi Intecc Co., Ltd.
Listing: Tokyo Stock Exchange and Nagoya Stock Exchange
Securities code: 7747
URL: https://www.asahi-intecc.co.jp/
Representative: Kenji Miyata, President & CEO
Inquiries: Mizuho Ito, Member of Board & CFO, General Manager of Administration
Telephone: +81-561-56-1851
Scheduled date of annual general meeting of shareholders: September 29, 2026
Scheduled date of commencing dividend payments: September 30, 2026
Scheduled date of filing annual securities report: September 28, 2026
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the fiscal year ended June 30, 2026 (from July 1, 2025 to June 30, 2026)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Fiscal year ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
June 30, 2026	145,419	21.2	45,218	50.3	45,185	52.8	32,075	151.8
June 30, 2025	120,025	11.6	30,079	35.9	29,563	34.6	12,737	-19.4

Note: Comprehensive income For the fiscal year ended June 30, 2026: ¥40,065 million (327.4%)
For the fiscal year ended June 30, 2025: ¥9,375 million (-59.0%)

	Basic earnings per share	Diluted earnings per share	Return on equity	Ordinary profit to total assets ratio	Operating profit to net sales ratio
Fiscal year ended	Yen	Yen	%	%	%
June 30, 2026	120.59	–	19.8	22.0	31.1
June 30, 2025	46.92	–	8.4	15.4	25.1

Reference: Share of profit (loss) of entities accounted for using equity method
For the fiscal year ended June 30, 2026: ¥– million
For the fiscal year ended June 30, 2025: ¥– million

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
June 30, 2026	218,285	174,358	79.4	653.57
June 30, 2025	193,187	151,354	77.9	558.31

Reference: Equity
As of June 30, 2026: ¥173,406 million
As of June 30, 2025: ¥150,558 million

(3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
Fiscal year ended	Million yen	Million yen	Million yen	Million yen
June 30, 2026	40,095	-11,739	-19,971	64,264
June 30, 2025	40,543	-13,434	-8,107	53,200

2. Dividends

	Annual dividends per share					Total dividends (total)	Payout ratio (consolidated)	Dividends to net assets ratio (consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
Fiscal year ended	Yen	Yen	Yen	Yen	Yen	Million yen	%	%
June 30, 2025	–	0.00	–	24.23	24.23	6,534	51.6	4.3
June 30, 2026	–	0.00	–	48.24	48.24	12,799	40.0	8.0
Fiscal year ending June 30, 2027 (Forecast)	–	0.00	–	49.91	49.91		35.0	

Breakdown of year-end dividend for the fiscal year ended June 30, 2026

Ordinary dividend: 42.21 yen

Commemorative dividend: 6.03 yen

3. Consolidated financial results forecast for the fiscal year ending June 30, 2027 (July 1, 2026 to June 30, 2027)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	161,794	11.3	52,127	15.3	52,600	16.4	37,832	17.9	142.59

* Notes

(1) Significant changes in scope of consolidation during the period: None
Newly included: -
Excluded: -

(2) Changes in accounting policies, changes in accounting estimates, and restatement
- (i) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes
- (ii) Changes in accounting policies due to other reasons: None
- (iii) Changes in accounting estimates: None
- (iv) Restatement: None

(3) Number of issued shares (common stock)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2026	265,332,300 shares
As of June 30, 2025	271,633,600 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2026	7,977 shares
As of June 30, 2025	1,964,677 shares

(iii) Average number of shares during the period (cumulative)

Fiscal year ended June 30, 2026	265,996,421 shares
Fiscal year ended June 30, 2025	271,476,579 shares

(Reference) Summary of Non-Consolidated Financial Results

1. Non-consolidated financial results for the fiscal year ended June 30, 2026 (from July 1, 2025 to June 30, 2026)

(1) Non-consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit	
Fiscal year ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
June 30, 2026	99,750	15.3	31,783	47.9	35,975	-1.9	26,796	23.7
June 30, 2025	86,493	17.2	21,496	55.3	36,685	163.5	21,662	98.8

	Basic earnings per share	Diluted earnings per share
Fiscal year ended	Yen	Yen
June 30, 2026	100.74	–
June 30, 2025	79.79	–

(2) Non-consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
June 30, 2026	175,684	118,969	67.7	448.39
June 30, 2025	155,316	108,840	70.1	403.61

Reference: Equity
As of June 30, 2026: ¥118,969 million
As of June 30, 2025: ¥108,840 million

* Financial results reports are exempt from review by certified public accountants or an audit corporation.
* Proper use of earnings forecasts, and other special matters

  Financial results forecasts and other forward-looking statements provided in these materials are based on information available to the Company and certain other assumptions deemed reasonable as of the date of publication of this document, and do not represent any guarantee that the Company will achieve these results. Actual financial results and other aspects of business performance may differ significantly from these forecasts owing to various factors. Please refer to “1. Overview of operating results, etc. (4) Future outlook” on page 4 of the attached materials for conditions forming the basis for financial results forecasts, notes regarding the use of financial results forecasts, and other information.

Table of contents of the attached materials

1. Overview of operating results, etc.

(1) Overview of operating results for the fiscal year under review

The Asahi Intecc Group (the Group) aims to maintain a high level of growth and further enhance its corporate value by steadily promoting the growth strategies set forth in its new medium-term management plan, “Building the Future 2030,” which began in the fiscal year ended June 30, 2026.

The Group’s performance for the fiscal year ended June 30, 2026 progressed favorably, as follows.

Net sales amounted to 145,419 million yen (an increase of 21.2% year on year), driven by the strong performance of both the Medical and Device Divisions, as well as the impact of foreign exchange rates.

Gross profit totaled 102,447 million yen (an increase of 26.1% year on year), due to the increase in net sales, the impact of foreign exchange rates, and improvement in the gross profit margin in line with productivity improvements, despite an increase in U.S. tariffs.

Operating profit was 45,218 million yen (an increase of 50.3% year on year), due to the increase in net sales, productivity improvements, and the impact of foreign exchange rates, despite an increase in selling, general and administrative expenses, such as an increase in sales-related expenses aimed at strengthening sales in the U.S. and R&D expenses.

Ordinary profit was 45,185 million yen (an increase of 52.8% year on year), due to an increase in operating profit and a decrease in foreign exchange losses, despite a decrease in subsidy income.

Profit attributable to owners of parent was 32,075 million yen (an increase of 151.8% year on year), due to an increase in ordinary profit and a significant decrease in impairment losses.

Foreign exchange rates used for the fiscal year under review:

154.45 yen per U.S. dollar (149.72 yen for the same period of the previous fiscal year, up 3.2%)

180.11 yen per euro (162.83 yen for the same period of the previous fiscal year, up 10.6%)

22.10 yen per Chinese yuan (20.73 yen for the same period of the previous fiscal year, up 6.6%)

4.80 yen per Thai baht (4.41 yen for the same period of the previous fiscal year, up 8.8%)

The operating results for each segment are outlined below.

<Medical Division>

In the Medical Division, net sales increased in all regions, both in Japan and overseas.

In the domestic market, net sales increased mainly due to strong performance of purchased peripheral vascular products in the non-cardiovascular field.

In the overseas market, net sales increased in both the cardiovascular and non-cardiovascular fields, supported also by the impact of foreign exchange rates. In the cardiovascular field, net sales increased primarily for PCI guide wires and penetration catheters in all regions. In the non-cardiovascular field, net sales increased due to growth in abdominal and peripheral vascular products in all regions, as well as an increase in neurovascular products across overseas markets.

As a result, net sales totaled 126,798 million yen (an increase of 17.6% year on year).

Segment profit amounted to 46,190 million yen (an increase of 38.1% year on year).

<Device Division>

In the Device Division, net sales increased due to the strong performance of both medical and industrial components, supported also by the impact of foreign exchange rates.

In addition, from the current fiscal year, Nitta Mold was included in the scope of consolidation as a consolidated subsidiary, and the company’s profit and loss were reflected in the Group’s consolidated results.

As for medical components, net sales increased mainly due to an increase in transactions in cardiovascular inspection catheter components for U.S. companies and transactions in cardiovascular ultrasound catheter components for Asia, as well as the consolidation of Nitta Mold as a subsidiary.

As for industrial components, net sales increased mainly due to an increase in leisure-related transactions in the overseas market and the consolidation of Nitta Mold as a subsidiary.

As a result, net sales totaled 18,620 million yen (an increase of 52.1% year on year).

Segment profit amounted to 8,485 million yen (an increase of 83.5% year on year), mainly due to an increase in revenues from external customers.

(2) Overview of financial position for the fiscal year under review

As of June 30, 2026, total assets amounted to 218,285 million yen, an increase of 25,098 million yen from the end of the previous fiscal year. This was mainly due to increases of 10,063 million yen in cash and deposits and 3,156 million yen in notes and accounts receivable - trade.

As for liabilities, total liabilities amounted to 43,927 million yen, an increase of 2,094 million yen from the end of the previous fiscal year. This was mainly due to increases of 1,996 million yen in notes and accounts payable - trade and 2,626 million yen in income taxes payable.

As for net assets, total net assets amounted to 174,358 million yen, an increase of 23,004 million yen from the end of the previous fiscal year. This was mainly due to increases of 13,487 million yen in retained earnings and 7,285 million yen in foreign currency translation adjustment.

(3) Overview of cash flows for the fiscal year under review

The balance of cash and cash equivalents (hereinafter, “net cash”) during the fiscal year under review was 64,264 million yen (an increase of 20.8% year on year).

The status of cash flows and their factors during the fiscal year under review are as follows.

(Cash flows from operating activities)

Net cash provided by operating activities was 40,095 million yen (a decrease of 447 million yen year on year). This was mainly due to profit before income taxes of 44,695 million yen, depreciation of 8,799 million yen, and increase in trade payables of 2,269 million yen, despite income taxes paid of 9,168 million yen, decrease in advances received of 5,178 million yen, increase in trade receivables of 1,594 million yen, and increase in inventories of 1,528 million yen.

(Cash flows from investing activities)

Net cash used in investing activities was 11,739 million yen (a decrease of 1,694 million yen year on year). This was mainly due to purchase of investment securities of 6,886 million yen and purchase of property, plant and equipment of 8,383 million yen, despite proceeds from sale of investment securities of 4,020 million yen.

(Cash flows from financing activities)

Net cash used in financing activities was 19,971 million yen (an increase of 11,864 million yen year on year). This was mainly due to repayments of long-term borrowings of 2,381 million yen, dividends paid of 6,534 million yen, and purchase of treasury shares of 10,553 million yen.

(4) Future outlook

The Group is steadily promoting the strategies and measures set forth in its medium-term management plan, “Building the Future 2030 – Unlocking Sustainable Growth.” In addition to expanding sales and market share across regions and businesses, productivity improvements are progressing beyond initial expectations.

The consolidated financial results forecast for the fiscal year ending June 30, 2027 has been formulated based on this progress in business activities, recent foreign exchange trends, and other factors.

For details of the revisions to the numerical targets of the medium-term management plan, please refer to the “Notice concerning Upward Revision of the Numerical Targets of the Medium-Term Management Plan ‘Building the Future 2030’ and the Long-Term Vision,” released on August 14, 2026.

(Million yen)

	Fiscal year ended June 30, 2026 Results	Fiscal year ending June 30, 2027 Forecast	Increase (Decrease)	Increase (Decrease) (%)
Net sales	145,419	161,794	16,374	11.3
Gross profit	102,447	114,737	12,289	12.0
(Percentage)	70.4	70.9	0.5	-
Operating profit	45,218	52,127	6,908	15.3
(Percentage)	31.1	32.2	1.1	-
Profit attributable to owners of parent	32,075	37,832	5,756	17.9

In this business forecast, the foreign exchange rates for major currencies are assumed as follows.

(Yen)	U.S. dollar	Euro	Chinese yuan	Thai baht
Fiscal year ending June 30, 2027: assumption	155.00	179.00	22.00	4.90
Fiscal year ended June 30, 2026: actual rate	154.45	180.11	22.10	4.80

<Net sales>

(Medical Division)

In the Medical Division, net sales are expected to increase mainly due to strong growth in the overseas market.

<Our own brand>

In the domestic market, net sales are expected to increase mainly due to strong performance of purchased peripheral vascular products in the non-cardiovascular field.

In the overseas market, through continued efforts to expand market share and other measures, net sales are expected to increase in both the cardiovascular field and the non-cardiovascular field in all regions. In the overseas cardiovascular field, since the number of cases is increasing significantly, mainly in the Chinese market, we will continue to aim for steady sales increase, as well as market share expansion. In the overseas non-cardiovascular field, net sales of abdominal vascular, peripheral vascular, and neurovascular products are expected to increase in all regions.

<OEM>

Net sales are expected to increase mainly due to an increase in overseas transactions, including transactions in peripheral arterial atherectomy catheters for the U.S. market.

(Device Division)

In the Device Division, net sales are expected to increase in both medical and industrial components.

As for medical components, net sales are expected to increase as demand for components used in diagnostic and therapeutic catheters in the cardiovascular field continues to grow, particularly among major medical device manufacturers in the U.S.

As for industrial components, net sales are expected to increase mainly due to strong performance of leisure-related and OA equipment-related transactions, despite a decrease in automobile-related transactions.

<Gross profit>

Gross profit is expected to increase along with an increase in revenue.

Gross profit margin is expected to increase due to the effects of productivity improvements and other factors, despite the impact of rising material costs and other factors.

<Selling, general and administrative expenses>

Selling, general and administrative expenses are expected to increase as we plan to continue upfront investments for future sustainable growth, despite an anticipated decrease in performance-linked bonuses.

As for R&D expenses, we plan to continue increasing them with a view to future growth, and the R&D-to-sales ratio is expected to be 9.4%.

Sales-related expenses are expected to increase as sales and marketing activities are strengthened in each region.

In addition, personnel expenses are expected to increase as we strengthen the company-wide organizational structure to accommodate future business expansion.

Furthermore, start-up-related expenses for Asahi Intecc Medical Device (Nanning) Co., Ltd. (Nanning Factory), which is scheduled to commence operations in 2030, are expected to increase as preparations for the commencement of operations enter a full-scale phase.

<Non-operating income/expenses and extraordinary income/losses>

We do not expect any transactions having significant impact on non-operating income or expenses and extraordinary income or losses.

(5) Basic policy on profit distribution and dividends for the fiscal year under review and next fiscal year

(Basic policy on profit distribution)

We conduct business operations on a global scale and always aim to enhance corporate value. We recognize that returning some of our profits from business activities to shareholders is one of our important issues and adopt the basic policy of stable and continual distribution of dividends in consideration of consolidated financial results and other factors from a long-term perspective.

As a basic policy, we distribute dividends of surplus once a year as the year-end dividend. The decision on dividends is made by the general meeting of shareholders. However, the Articles of Incorporation stipulates that by a resolution of the Board of Directors, interim dividends provided for in Article 454, Paragraph 5 of the Companies Act may be distributed to shareholders or registered pledgees of shares listed or recorded in the final shareholder register as of December 31 every year.

We calculate the amount of dividends based on a long-term perspective and in comprehensive consideration of consolidated financial results for the fiscal year under review, future outlooks, the level of internal reserves, etc., targeting a consolidated dividend payout ratio of 35.0%.

Internal reserves will be used for R&D and capital investment indispensable for future growth and thus, we will make efforts to increase business performance and strengthen the financial position.

(Profit distribution for the fiscal year under review and next fiscal year)

Based on the above policy, we plan to pay 48.24 yen as the annual dividend for the fiscal year under review (consolidated dividend payout ratio of 40.0%), comprising an ordinary dividend of 42.21 yen (consolidated dividend payout ratio of 35.0%) and a commemorative dividend of 6.03 yen to mark the 50th anniversary of the Company’s establishment. We plan to propose this matter at the Annual General Meeting of Shareholders to be held on September 29, 2026, and based on the resolution, the formal decision will be made and the payment will be executed.

In addition, based on the above policy, we plan to pay 49.91 yen as the annual dividend for the next fiscal year (consolidated dividend payout ratio of 35.0%).

Dividends of surplus whose record date falls in the fiscal year under review are as follows:

Resolution date	Total amount of dividends	Dividend per share
September 29, 2026 Resolution at Annual General Meeting of Shareholders	12,799 million yen	48.24 yen

2. Basic policy on selection of accounting standards

   The Group's policy is to prepare consolidated financial statements in accordance with Japanese GAAP for the time being, taking into consideration the comparability of consolidated financial statement from period to period and from company to company.

   As for the application of International Financial Reporting Standards (IFRS), the Group's policy is to take appropriate measures in consideration of various domestic and international circumstances.

3. Consolidated financial statements and major notes

(1) Consolidated balance sheet

(Million yen)

	Previous consolidated fiscal year (June 30, 2025)	Current consolidated fiscal year (June 30, 2026)
Assets		
Current assets		
Cash and deposits	54,200	64,264
Notes and accounts receivable - trade	15,767	18,923
Electronically recorded monetary claims - operating	2,026	2,080
Merchandise and finished goods	9,408	10,111
Work in process	8,785	10,482
Raw materials and supplies	6,458	9,240
Other	7,004	6,791
Allowance for doubtful accounts	-291	-325
Total current assets	103,359	121,569
Non-current assets		
Property, plant and equipment		
Buildings and structures	49,407	55,364
Accumulated depreciation	-16,884	-20,845
Buildings and structures, net	32,523	34,518
Machinery, equipment and vehicles	36,847	42,222
Accumulated depreciation	-28,008	-33,051
Machinery, equipment and vehicles, net	8,838	9,171
Land	7,301	7,841
Construction in progress	3,758	4,700
Other	15,851	17,725
Accumulated depreciation	-9,190	-10,870
Other, net	6,661	6,854
Total property, plant and equipment	59,082	63,087
Intangible assets		
Goodwill	110	–
Other	5,485	5,118
Total intangible assets	5,595	5,118
Investments and other assets		
Investment securities	19,389	24,251
Shares of subsidiaries and associates	335	0
Deferred tax assets	1,779	1,641
Other	4,384	3,519
Allowance for doubtful accounts	-739	-901
Total investments and other assets	25,149	28,510
Total non-current assets	89,827	96,716
Total assets	193,187	218,285

(Million yen)

	Previous consolidated fiscal year (June 30, 2025)	Current consolidated fiscal year (June 30, 2026)
Liabilities		
Current liabilities		
Notes and accounts payable - trade	2,655	4,652
Electronically recorded obligations - operating	424	1,242
Short-term borrowings	2,387	2,357
Accounts payable - other	1,805	2,602
Income taxes payable	4,789	7,416
Provision for bonuses	2,868	4,062
Other	12,924	9,790
Total current liabilities	27,856	32,124
Non-current liabilities		
Long-term borrowings	6,633	4,275
Deferred tax liabilities	1,929	1,938
Provision for retirement benefits for directors (and other officers)	19	19
Retirement benefit liability	2,943	3,147
Asset retirement obligations	197	201
Lease liabilities	2,078	2,031
Other	174	189
Total non-current liabilities	13,976	11,803
Total liabilities	41,833	43,927
Net assets		
Shareholders' equity		
Share capital	18,860	18,860
Capital surplus	21,779	18,872
Retained earnings	97,947	111,434
Treasury shares	-4,453	-18
Total shareholders' equity	134,134	149,148
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	2,008	2,429
Foreign currency translation adjustment	14,315	21,601
Remeasurements of defined benefit plans	99	227
Total accumulated other comprehensive income	16,424	24,258
Non-controlling interests	795	951
Total net assets	151,354	174,358
Total liabilities and net assets	193,187	218,285

(2) Consolidated statements of income and comprehensive income

Consolidated statement of income

(Million yen)

	Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)	Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)
Net sales	120,025	145,419
Cost of sales	38,789	42,972
Gross profit	81,235	102,447
Selling, general and administrative expenses		
Freight-out	2,949	3,495
Provision of allowance for doubtful accounts	58	42
Salaries, wages and bonuses	12,926	14,792
Remuneration for directors (and other officers)	694	720
Director’s bonuses	–	246
Provision for bonuses	1,458	1,935
Retirement benefit expenses	441	475
Depreciation	3,002	3,052
Research and development expenses	12,248	13,372
Other	17,376	19,093
Total selling, general and administrative expenses	51,155	57,228
Operating profit	30,079	45,218
Non-operating income		
Interest income	115	220
Dividend income	128	89
Subsidy income	918	241
Other	239	196
Total non-operating income	1,401	747
Non-operating expenses		
Interest expenses	214	133
Commission for purchase of treasury shares	8	94
Foreign exchange losses	1,455	258
Provision of allowance for doubtful accounts	9	156
Other	229	137
Total non-operating expenses	1,918	780
Ordinary profit	29,563	45,185
Extraordinary income		
Gain on sale of investment securities	23	1,527
Reversal of allowance for doubtful accounts	100	–
Total extraordinary income	123	1,527
Extraordinary losses		
Impairment losses	* 9,244	* 1,061
Loss on valuation of investment securities	1,068	156
Loss on valuation of shares of subsidiaries and associates	210	794
Provision of allowance for doubtful accounts for subsidiaries and associates	477	–
Other	31	6
Total extraordinary losses	11,031	2,018
Profit before income taxes	18,655	44,695
Income taxes - current	9,147	12,581
Income taxes - deferred	-3,284	-37
Total income taxes	5,863	12,544
Profit	12,792	32,150
Profit attributable to non-controlling interests	54	75
Profit attributable to owners of parent	12,737	32,075

Consolidated statement of comprehensive income

(Million yen)

	Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)	Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)
Profit	12,792	32,150
Other comprehensive income		
Valuation difference on available-for-sale securities	-680	420
Foreign currency translation adjustment	-2,826	7,365
Remeasurements of defined benefit plans, net of tax	90	127
Total other comprehensive income	-3,417	7,914
Comprehensive income	9,375	40,065
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	9,323	39,909
Comprehensive income attributable to non-controlling interests	51	155

(3) Consolidated statement of changes in equity

Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)

(Million yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	18,860	21,779	90,742	-7	131,375
Changes during period					
Dividends of surplus			-5,533		-5,533
Profit attributable to owners of parent			12,737		12,737
Purchase of treasury shares				-4,446	-4,446
Cancellation of treasury shares					–
Increase in retained earnings of subsidiaries due to change in scope of consolidation					–
Net changes in items other than shareholders' equity					
Total changes during period	–	–	7,204	-4,446	2,758
Balance at end of period	18,860	21,779	97,947	-4,453	134,134

	Accumulated other comprehensive income				Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at beginning of period	2,689	17,142	9	19,841	744	151,961
Changes during period						
Dividends of surplus						-5,533
Profit attributable to owners of parent						12,737
Purchase of treasury shares						-4,446
Cancellation of treasury shares						–
Increase in retained earnings of subsidiaries due to change in scope of consolidation				–		–
Net changes in items other than shareholders' equity	-680	-2,826	90	-3,417	51	-3,365
Total changes during period	-680	-2,826	90	-3,417	51	-607
Balance at end of period	2,008	14,315	99	16,424	795	151,354

Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)

(Million yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	18,860	21,779	97,947	-4,453	134,134
Changes during period					
Dividends of surplus			-6,534		-6,534
Profit attributable to owners of parent			32,075		32,075
Purchase of treasury shares				-10,553	-10,553
Cancellation of treasury shares		-2,907	-12,080	14,988	–
Increase in retained earnings of subsidiaries due to change in scope of consolidation			26		26
Net changes in items other than shareholders' equity					
Total changes during period	–	-2,907	13,487	4,434	15,014
Balance at end of period	18,860	18,872	111,434	-18	149,148

	Accumulated other comprehensive income				Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at beginning of period	2,008	14,315	99	16,424	795	151,354
Changes during period						
Dividends of surplus						-6,534
Profit attributable to owners of parent						32,075
Purchase of treasury shares						-10,553
Cancellation of treasury shares						–
Increase in retained earnings of subsidiaries due to change in scope of consolidation						26
Net changes in items other than shareholders' equity	420	7,285	127	7,834	155	7,989
Total changes during period	420	7,285	127	7,834	155	23,004
Balance at end of period	2,429	21,601	227	24,258	951	174,358

(4) Consolidated statement of cash flows

(Million yen)

	Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)	Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)
Cash flows from operating activities		
Profit before income taxes	18,655	44,695
Depreciation	9,190	8,799
Increase (decrease) in allowance for doubtful accounts	427	179
Increase (decrease) in provision for bonuses	216	1,064
Increase (decrease) in retirement benefit liability	418	215
Interest and dividend income	-244	-309
Interest expenses	214	133
Amortization of goodwill	955	117
Loss (gain) on valuation of investment securities	1,068	156
Loss (gain) on sale of investment securities	5	-1,521
Impairment losses	9,244	1,061
Decrease (increase) in trade receivables	1,166	-1,594
Decrease (increase) in inventories	3,540	-1,528
Decrease (increase) in accounts receivable - other	-110	-42
Increase (decrease) in trade payables	190	2,269
Increase (decrease) in accounts payable - other	-851	669
Increase (decrease) in advances received	1,679	-5,178
Other, net	987	-63
Subtotal	46,756	49,122
Interest and dividends received	249	276
Interest paid	-248	-134
Income taxes paid	-6,213	-9,168
Net cash provided by (used in) operating activities	40,543	40,095

(Million yen)

	Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)	Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)
Cash flows from investing activities		
Proceeds from redemption of securities	3,000	–
Purchase of property, plant and equipment	-8,096	-8,383
Purchase of intangible assets	-482	-549
Purchase of investment securities	-14,325	-6,886
Proceeds from sale of investment securities	8,041	4,020
Other, net	-1,571	60
Net cash provided by (used in) investing activities	-13,434	-11,739
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	-1,000	–
Proceeds from long-term borrowings	8,500	–
Repayments of long-term borrowings	-5,182	-2,381
Purchase of treasury shares	-4,446	-10,553
Dividends paid	-5,533	-6,534
Repayments of lease liabilities	-446	-502
Net cash provided by (used in) financing activities	-8,107	-19,971
Effect of exchange rate change on cash and cash equivalents	-1,459	2,226
Net increase (decrease) in cash and cash equivalents	17,542	10,610
Cash and cash equivalents at beginning of period	35,658	53,200
Increase (decrease) in cash and cash equivalents resulting from change in scope of consolidation	–	452
Cash and cash equivalents at end of period	53,200	64,264

(5) Notes to consolidated financial statements

(Note on entity's ability to continue as going concern)

Not applicable.

(Significant accounting policies for preparation of consolidated financial statements)

1. Scope of consolidation

(1) Number of consolidated subsidiaries 20

(2) Names of major consolidated subsidiaries

ASAHI INTECC THAILAND CO., LTD.

ASAHI INTECC HANOI CO., LTD.

TOYOFLEX CEBU CORPORATION

Filmecc Co., Ltd.

ASAHI INTECC J-Sales CO., LTD.

ASAHI INTECC USA, INC.

Filmecc USA, Inc.

ASAHI INTECC SCIENTIFIC (Beijing) Co., Ltd.

ASAHI INTECC EUROPE B.V.

During the fiscal year under review, Nitta Mold Co., Ltd. and its subsidiary, NITTA M&T (THAILAND) CO., LTD., were included in the scope of consolidation due to an increase in materiality.

(3) Names of non-consolidated subsidiaries

Nihon Chemical Coat Co., Ltd.

FICUS Co., Ltd.

walkey Inc.

LAKE R&D Inc.

Magnaire Co., Ltd.

Reason for exclusion from the scope of consolidation

The five non-consolidated subsidiaries are small in size, and the total assets, net sales, profit or loss (the Company's share), retained earnings (the Company's share), etc. of these companies do not have a material impact on the consolidated financial statements.

2. Application of the equity method

Names of major non-consolidated subsidiaries and affiliated companies not accounted for using the equity method

Nihon Chemical Coat Co., Ltd.

FICUS Co., Ltd.

walkey Inc.

LAKE R&D Inc.

Magnaire Co., Ltd.

Reason for not applying the equity method

As for the seven non-consolidated subsidiaries and affiliated companies not accounted for using the equity method, the impact of excluding them from the scope of equity method on the consolidated financial statements is minimal given their profit or loss (the Company's share), retained earnings (the Company's share), etc., and the impact is immaterial as a whole.

3. Fiscal years of consolidated subsidiaries

Out of the Company's consolidated subsidiaries, ASAHI INTECC SCIENTIFIC (Beijing) Co., Ltd., Asahi Intecc Medical Device (Nanning) Co., Ltd., and ASAHI INTECC CIS LLC end their fiscal years on December 31.

When preparing the consolidated financial statements, financial statements based on a provisional settlement of accounts conducted as of the consolidated fiscal year-end are used for these companies.

4. Accounting policies

(1) Basis and method of valuation of important assets

a) Securities

Securities to be held to maturity

Cost method

Available-for-sale securities

Securities other than shares that do not have a market value

Measured at fair value

(Valuation differences are reported as a component of net assets. The cost of securities sold is calculated using the moving-average method.)

Shares that do not have a market value

Measured at cost using the moving-average method

b) Inventories

Merchandise and finished goods, work in process, and raw materials

Measured at cost, primarily determined by the periodic average method

(The carrying amount in the balance sheet is calculated with consideration of write-downs due to decreased profitability.)

Supplies

Measured at cost, determined by the last purchase price method

(The carrying amount in the balance sheet is calculated with consideration of write-downs due to decreased profitability.)

(2) Method of depreciation and amortization of important depreciable and amortizable assets

a) Property, plant and equipment (excluding leased assets)

Depreciated mainly using the straight-line method.

The range of useful lives is as follows:

Buildings and structures	8 to 47 years
Machinery, equipment and vehicles	5 to 10 years

b) Intangible assets

Amortized using the straight-line method.

The Company and its consolidated subsidiaries in Japan amortize software for internal use over the expected useful life within respective companies (five years).

c) Leased assets

Amortized using the straight-line method based on the assumption that the useful lives are equivalent to the lease terms and the residual value is zero.

Leased assets are presented as part of "other" under "property, plant and equipment."

(3) Basis for recording important provisions

a) Allowance for doubtful accounts

At the Company and its consolidated subsidiaries in Japan, allowance for doubtful accounts is provided for possible losses arising from bad debts at an amount determined based on the historical default rates for general receivables, and an individual estimate of uncollectible amounts for specific doubtful receivables from customers experiencing financial difficulties.

At overseas consolidated subsidiaries, allowance for doubtful accounts is provided at an amount determined based on an individual estimate of uncollectible amounts.

b) Provision for bonuses

Provision for bonuses is recorded at an estimated amount attributable to the fiscal year under review to provide for future bonus payments to employees.

c) Provision for retirement benefits for directors (and other officers)

The Company abolished the officer retirement benefit system in September 2005. The balance of provision for retirement benefits for directors (and other officers) as of the end of the fiscal year under review is the estimated amount to be paid to officers who were in office when the system was abolished. The payments will be made when each officer retires.

(4) Basis for accounting treatments on retirement benefit

Retirement benefit liability is recorded at an estimated amount of retirement benefit obligations and pension assets as of the end of the fiscal year under review to provide for future retirement benefits to employees.

(i) Method for attributing estimated retirement benefits to individual periods of service

In calculating the retirement benefit obligations, the benefit formula basis is adopted for the purpose of attributing estimated retirement benefits to the period up to the end of the fiscal year under review.

(ii) Calculation of actuarial gain or loss and prior service cost

Actuarial gain or loss is amortized from the following fiscal year on a straight-line basis over a certain period shorter than the average remaining years of service of the eligible employees at the time of the gain or loss arising during each fiscal year (primarily five years).

Prior service cost is amortized on a straight-line basis over a certain period (12 years), which is within the average remaining years of service period of the eligible employees at the time the cost arising.

(iii) Adoption of short-cut method at small companies, etc.

Certain consolidated subsidiaries apply the short-cut method when calculating retirement benefit liability and retirement benefit expenses, under which the amount of retirement benefit that must be paid if employees retire for personal reasons at the end of the fiscal year is deemed to be the amount of retirement benefit obligations.

(5) Significant revenue and expense recognition standards

The details of main performance obligations in main businesses related to revenue arising from contracts with customers of the Company and its consolidated subsidiaries and the usual timing of fulfillment of the performance obligation (the usual timing of revenue recognition) are as follows.

The Medical Division mainly engages in sales of medical products and the Device Division mainly engages in sales of industrial products. Regarding sales of these products, revenue is mainly recognized when goods and products are each delivered to a customer, because at such time, legal ownership, physical possession, material risk associated with ownership, and economic value of those goods and products are transferred to the customer and the right to receive payment is finalized.

The consideration under sales contracts of the Group’s products is generally received within one to three months after delivery of products to a customer based on contracts with customers and does not include significant financial elements.

(6) Translation of significant assets and liabilities denominated in foreign currencies into Japanese yen

Receivables and payables denominated in foreign currencies are translated into Japanese yen at the exchange rate prevailing at the end of the consolidated fiscal year and resulting exchange gains and losses are included in net profit or loss. Assets and liabilities of overseas consolidated subsidiaries are translated into yen at the exchange rate prevailing on the respective fiscal year-ends of those subsidiaries. Income and expenses are translated at the average rate of market price during the fiscal year and resulting translation adjustments are included in net assets as foreign currency translation adjustment under accumulated other comprehensive income.

(7) Amortization method and period of goodwill

Goodwill is amortized using the straight-line method over five to twenty years.

(8) Scope of funds in the consolidated statement of cash flows

These funds include cash on hand, deposits that can be withdrawn on demand, and short-term investments that can be easily converted into cash and bear only minor risks with respect to fluctuation of value with their redemption deadline arriving within three months from the acquisition date.

(Changes in accounting policies)

(Application of the "Practical Solution on the Accounting for and Disclosure of Current Taxes Related to the Global Minimum Tax Rules," etc.)

The Company has applied the "Practical Solution on the Accounting for and Disclosure of Current Taxes Related to the Global Minimum Tax Rules" (Practical Solution No. 46, March 22, 2024), etc. from the beginning of the fiscal year under review.
The impact of this change in accounting policy on the consolidated financial statements is immaterial.

(Changes in presentation)

(Consolidated statement of income)

"Commission for purchase of treasury shares" and "provision of allowance for doubtful accounts," which were included in "other" under "non-operating expenses" for the previous fiscal year, are presented separately from the current fiscal year due to an increase in financial materiality. To reflect this change in presentation, the consolidated financial statements for the previous fiscal year have been reclassified.

As a result, in the consolidated statement of income for the previous fiscal year, 247 million yen presented as "other" under "non-operating expenses" has been reclassified as 8 million yen presented as "commission for purchase of treasury shares," 9 million yen presented as "provision of allowance for doubtful accounts," and 229 million yen presented as "other."

(Consolidated statement of cash flows)

"Loss (gain) on sale of investment securities," which was included in "other" under "cash flows from operating activities" for the previous fiscal year, is presented separately from the current fiscal year due to an increase in financial materiality. To reflect this change in presentation, the consolidated financial statements for the previous fiscal year have been reclassified.

As a result, in the consolidated statement of cash flows for the previous fiscal year, 992 million yen presented as "other" under "cash flows from operating activities" has been reclassified as 5 million yen presented as "loss (gain) on sale of investment securities" and 987 million yen presented as "other."

(Consolidated statement of income)

*Impairment losses

Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)

During the fiscal year under review, the Group recorded impairment losses related to the following asset groups.

Subsidiary (Location)	Use	Type	Impairment loss (Million yen)
ASAHI SURGICAL ROBOTICS CO., LTD. (Kashiwa, Chiba)	Business assets	Goodwill and other intangible assets, etc.	1,992
Pathways Medical Corporation (California, USA)	Business assets	Goodwill and other intangible assets, etc.	3,636
Rev.1 Engineering, Inc. (California, USA)	Business assets	Goodwill and other intangible assets, etc.	1,623
ASAHI Medical Technologies, Inc. (California, USA)	Business assets	Goodwill, etc.	1,991

The Group defines asset groups based on managerial accounting units, grouping them by the smallest units that generate independent cash flows.

Considering the business environment and future business plans, it was determined that the investments in the above consolidated subsidiaries were no longer recoverable mainly due to a decline in profitability. Accordingly, impairment losses were recorded on goodwill and other intangible assets, etc.
The recoverable amount was calculated based on value in use. However, following a review of future plans, the cash outflows required to maintain and operate the assets over the estimation period were determined to exceed the cash inflows generated by their use, and accordingly, the value in use was calculated as zero.

Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)

During the current fiscal year, the Group recorded impairment losses related to the following asset groups.

Company (Location)	Use	Type	Impairment loss (Million yen)
Asahi Intecc Co., Ltd. (Seto, Aichi)	Business assets	Other under investments and other assets	1,061

The Group defines asset groups based on managerial accounting units, grouping them by the smallest units that generate independent cash flows.

The Company and Magnaire Co., Ltd. had been jointly developing products with MagneDesign Corporation. However, during the current fiscal year, the sales and development plans were revised. Following this revision, and considering the future business environment and business plans, it was determined that the investment was no longer recoverable mainly due to a decline in profitability. Accordingly, an impairment loss was recorded on other under investments and other assets.
The recoverable amount was calculated based on value in use. However, following a review of future plans, the cash outflows required to maintain and operate the assets were determined to exceed the cash inflows generated by their use, and accordingly, the value in use was calculated as zero.

(Consolidated statement of changes in equity)

Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)

1. Matters concerning the class and total number of issued shares and the class and number of treasury shares

Class of shares	Number of shares at the beginning of the fiscal year under review (shares)	Increase (shares)	Decrease (shares)	Number of shares at the end of the fiscal year under review (shares)
Issued shares				
Common shares	271,633,600	–	–	271,633,600
Treasury shares				
Common shares	7,955	1,956,722	–	1,964,677

(Summary of the changes)

Treasury shares

Increase due to purchase of shares less than one unit: 22 shares

Increase due to market purchase for acquisition of treasury shares: 1,956,700 shares

Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)

1. Matters concerning the class and total number of issued shares and the class and number of treasury shares

Class of shares	Number of shares at the beginning of the fiscal year under review (shares)	Increase (shares)	Decrease (shares)	Number of shares at the end of the fiscal year under review (shares)
Issued shares				
Common shares	271,633,600	–	6,301,300	265,332,300
Treasury shares				
Common shares	1,964,677	4,344,600	6,301,300	7,977

(Summary of the changes)

Common shares

Decrease due to cancellation of treasury shares: 6,301,300 shares

Treasury shares

Increase due to market purchase for acquisition of treasury shares: 4,344,600 shares

Decrease due to cancellation of treasury shares: 6,301,300 shares

(Revenue recognition)

(1) Disaggregation of revenue from contracts with customers

1. Breakdown by type

Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Cardiovascular	81,202	–	81,202
Non-cardiovascular	18,983	–	18,983
OEM	7,593	–	7,593
Medical Components	–	8,019	8,019
Industrial Components	–	4,226	4,226
Total	107,779	12,245	120,025

Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Cardiovascular	94,778	–	94,778
Non-cardiovascular	24,370	–	24,370
OEM	7,650	–	7,650
Medical Components	–	11,859	11,859
Industrial Components	–	6,760	6,760
Total	126,798	18,620	145,419

2. Breakdown by region

Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Japan	16,074	2,805	18,880
North America	23,043	3,975	27,018
Europe	24,148	496	24,645
China	28,283	539	28,823
Others	16,229	4,428	20,658
Total	107,779	12,245	120,025

Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Japan	17,111	3,732	20,844
North America	26,186	6,624	32,811
Europe	27,873	575	28,449
China	37,417	564	37,982
Others	18,209	7,122	25,332
Total	126,798	18,620	145,419

(2) Underlying information for understanding revenue from contracts with customers

Useful information in understanding revenue is as presented in "(Significant accounting policies for preparation of consolidated financial statements), 4. Accounting policies, (5) Significant revenue and expense recognition standards."

(3) Information on relationship of fulfillment of performance obligations based on contracts with customers with cash flow generated from said contracts and the amount and period of revenue expected to be recognized in the next and subsequent fiscal years from contracts with customers' existing at the end of the fiscal year under review

Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)

1. Balance of contract liabilities, etc.

(Million yen)

	Fiscal year under review
Contract liabilities (beginning balance)	8,182
Contract liabilities (ending balance)	9,184

Contract liabilities are mainly related to advances received from customers. Contract liabilities are reversed upon recognition of revenue.

Revenue recognized in the fiscal year under review that was included in the contract liability balance at the beginning of the fiscal year under review was 8,182 million yen. The increase of 1,001 million yen in contract liabilities in the fiscal year under review was mainly attributable to an increase in advances received.

2. Transaction price allocated to the remaining performance obligations

The Group has applied a practical expedient and does not provide information on the remaining performance obligations as the Group has no significant transaction of which the original expected period is one year or more. Consideration promised in contracts with customers does not have any significant amounts not included in the transaction price.

Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)

1. Balance of contract liabilities, etc.

(Million yen)

	Fiscal year under review
Contract liabilities (beginning balance)	9,184
Contract liabilities (ending balance)	5,204

Contract liabilities are mainly related to advances received from customers. Contract liabilities are reversed upon recognition of revenue.

Revenue recognized in the current fiscal year that was included in the contract liability balance at the beginning of the current fiscal year was 9,184 million yen. The decrease of 3,980 million yen in contract liabilities in the current fiscal year was mainly attributable to a decrease in advances received.

2. Transaction price allocated to the remaining performance obligations

The Group has applied a practical expedient and does not provide information on the remaining performance obligations as the Group has no significant transaction of which the original expected period is one year or more. Consideration promised in contracts with customers does not have any significant amounts not included in the transaction price.

(Segment Information, etc.)

[Segment Information]

1. Description of reportable segments

   The Company's reportable segments are components of the Company for which separate financial information is available and subject to periodical reviews by the Board of Directors to determine allocation of management resources and evaluate business performance.

   The Group has established operating divisions by business area to conduct integrated business activities from development to manufacturing and sales. Based on these operating divisions, the Medical Division and the Device Division have been established as two reportable segments.

   The Medical Division engages in development, manufacturing and sales of our own brand products and OEM products in the medical device field and the Device Division engages in development, manufacturing and sales of components and other products in the medical device and industrial device fields.

2. Explanation of measurements of sales, profit (loss), asset, liability, and other items for each reportable segment

   The accounting method for the reported business segments is generally the same as the method stated in "significant accounting policies for preparation of consolidated financial statements."

   Profit of reportable segments is based on operating profit.

   Transactions with other segments are mainly based on market prices and manufacturing costs.

3. Disclosure of sales, profit (loss), asset, liability, and other items for each reportable segment
Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)

(Million yen)

	Reportable segment			Adjustments (Note 1)	Per consolidated financial statements (Note 2)
	Medical Division	Device Division	Total		
Net sales					
Revenues from external customers	107,779	12,245	120,025	–	120,025
Transactions with other segments	–	14,151	14,151	-14,151	–
Total	107,779	26,396	134,176	-14,151	120,025
Segment profit	33,445	4,624	38,069	-7,990	30,079
Segment assets	113,132	49,647	162,779	30,407	193,187
Other items					
Depreciation	5,190	3,427	8,617	572	9,190
Increase in property, plant and equipment and intangible assets	2,927	4,232	7,159	1,288	8,447

Notes: 1. Adjustments are as follows:
(i) The adjustment to segment profit includes corporate expenses that are not allocated to each reportable segment. Corporate expenses mainly consist of general and administrative expenses that do not belong to any reportable segment.
(ii) The adjustment to segment assets includes intersegment elimination of 259 million yen and corporate assets that are not allocated to each reportable segment of 30,148 million yen.
(iii) The adjustment to increase in property, plant and equipment and intangible assets includes an increase of corporate assets that do not belong to any reportable segment such as payment relating to the construction of welfare facilities.
2. Segment profit is adjusted with the operating profit in the consolidated statement of income.
3. Basis of allocation for non-current assets to each segment is different from that for related depreciation.

Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)

(Million yen)

	Reportable segment			Adjustments (Note 1)	Per consolidated financial statements (Note 2)
	Medical Division	Device Division	Total		
Net sales					
Revenues from external customers	126,798	18,620	145,419	–	145,419
Transactions with other segments	–	16,765	16,765	-16,765	–
Total	126,798	35,386	162,185	-16,765	145,419
Segment profit	46,190	8,485	54,676	-9,458	45,218
Segment assets	127,077	55,806	182,884	35,401	218,285
Other items					
Depreciation	4,670	3,543	8,214	584	8,799
Increase in property, plant and equipment and intangible assets	5,368	3,393	8,762	869	9,631

Notes: 1. Adjustments are as follows:

(i) The adjustment to segment profit includes corporate expenses that are not allocated to each reportable segment. Corporate expenses mainly consist of general and administrative expenses that do not belong to any reportable segment.

(ii) The adjustment to segment assets includes intersegment elimination of 287 million yen and corporate assets that are not allocated to each reportable segment of 35,114 million yen.

(iii) The adjustment to increase in property, plant and equipment and intangible assets includes an increase of corporate assets that do not belong to any reportable segment such as payment relating to the construction of welfare facilities.

2. Segment profit is adjusted with the operating profit in the consolidated statement of income.
3. Basis of allocation for non-current assets to each segment is different from that for related depreciation.

[Information associated with reportable segments]

Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)

1. Information for each product or service

This is omitted as the same information is disclosed in the segment information section.

2. Information for each region

(1) Net sales

(Million yen)

Japan	U.S.	Europe	China	Others	Total
18,880	26,381	24,645	28,823	21,295	120,025

Note: Net sales are classified by countries or regions based on the location of customers.

(2) Property, plant and equipment

(Million yen)

Japan	Thailand	Vietnam	Philippines	Others	Total
28,589	13,446	7,422	8,622	1,001	59,082

3. Information for each of main customers

(Million yen)

Name of customer	Net sales	Related segment
Beijing Jiashi Weizhong Medical Equipment Co., Ltd.	16,865	Medical Division

Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)

1. Information for each product or service

This is omitted as the same information is disclosed in the segment information section.

2. Information for each region

(1) Net sales

(Million yen)

Japan	U.S.	Europe	China	Others	Total
20,844	32,133	28,449	37,982	26,010	145,419

Note: Net sales are classified by countries or regions based on the location of customers.

(2) Property, plant and equipment

(Million yen)

Japan	Thailand	Vietnam	Philippines	Others	Total
29,669	15,098	8,184	7,603	2,531	63,087

3. Information for each of main customers

(Million yen)

Name of customer	Net sales	Related segment
Beijing Jiashi Weizhong Medical Equipment Co., Ltd.	17,793	Medical Division

[Disclosure of impairment losses on non-current assets for each reportable segment]
Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)

(Million yen)

	Reportable segment			Unallocated amounts and elimination	Total
	Medical Division	Device Division	Subtotal		
Impairment losses	9,244	–	9,244	–	9,244

Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)

(Million yen)

	Reportable segment			Unallocated amounts and elimination	Total
	Medical Division	Device Division	Subtotal		
Impairment losses	1,061	–	1,061	–	1,061

[Amortization and unamortized balance of goodwill for each reportable segment]
Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)

(Million yen)

	Reportable segment			Unallocated amounts and elimination	Total
	Medical Division	Device Division	Subtotal		
Amortization during the period	955	–	955	–	955
Balance at end of the period	110	–	110	–	110

Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)

(Million yen)

	Reportable segment			Unallocated amounts and elimination	Total
	Medical Division	Device Division	Subtotal		
Amortization during the period	117	–	117	–	117
Balance at end of the period	–	–	–	–	–

[Information about gain on bargain purchase for each reportable segment]
Not applicable.

(Per share information)

	Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)	Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)
Net assets per share	558.31 yen	653.57 yen
Basic earnings per share	46.92 yen	120.59 yen

Notes: 1. Diluted earnings per share is not presented because there are no potential shares with a dilutive effect.
2. The basis for calculating basic earnings per share is as follows.

Items	Previous consolidated fiscal year (from July 1, 2024 to June 30, 2025)	Current consolidated fiscal year (from July 1, 2025 to June 30, 2026)
Basic earnings per share		
Profit attributable to owners of parent (million yen)	12,737	32,075
Amount not attributable to common shareholders (million yen)	–	–
Profit attributable to owners of parent regarding common stock (million yen)	12,737	32,075
Average number of common stock during the period (thousand shares)	271,476	265,996

(Significant subsequent events)

Not applicable.